Literature DB >> 9704731

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.

J O Armitage1, D D Weisenburger.   

Abstract

Increasing knowledge about the biology of the non-Hodgkin's lymphomas has led to new approaches in classification. Rather than grouping lymphomas simply based on cell size, cell shape, and growth pattern, it is now possible to identify distinctive clinicopathologic entities. In many cases, the existence of specific immunologic and/or genetic features has confirmed the existence of these distinctive types of lymphoma. Since patients will be given these diagnoses by pathologists, it is important that clinicians be knowledgeable with regard to their clinical characteristics. The findings for the 13 most common lymphoma types that will be encountered in clinical practice are presented here.

Entities:  

Mesh:

Year:  1998        PMID: 9704731     DOI: 10.1200/JCO.1998.16.8.2780

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  249 in total

1.  A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254.

Authors:  Richard R Furman; Michael L Grossbard; Jeffrey L Johnson; Andrew L Pecora; Peter A Cassileth; Sin-Ho Jung; Bruce A Peterson; Lee M Nadler; Arnold Freedman; Ruthee-Lu Bayer; Nancy L Bartlett; David D Hurd; Bruce D Cheson
Journal:  Leuk Lymphoma       Date:  2011-01-28

2.  Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy.

Authors:  Kojo S J Elenitoba-Johnson; Stephen D Jenson; Robert T Abbott; Robert A Palais; Sandra D Bohling; Zhaosheng Lin; Sheryl Tripp; Paul J Shami; Lai Y Wang; Robert W Coupland; Rena Buckstein; Bayardo Perez-Ordonez; Sherrie L Perkins; Ian D Dube; Megan S Lim
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-19       Impact factor: 11.205

Review 3.  Therapy of non-Hodgkin's lymphoma.

Authors:  J Coffey; D C Hodgson; M K Gospodarowicz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-12       Impact factor: 9.236

Review 4.  Treatment of T-cell non-Hodgkin's lymphoma.

Authors:  Andrew M Evens; Ronald B Gartenhaus
Journal:  Curr Treat Options Oncol       Date:  2004-08

5.  A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential.

Authors:  Chung-Gi Lee; Bikul Das; Tara L Lin; Chelsea Grimes; Xin Zhang; Tracey Lavezzi; Li Huang; John Cole; Lillian Yau; Li Li
Journal:  Br J Haematol       Date:  2012-04-18       Impact factor: 6.998

6.  Bcl-2, Bcl-6, and the International Prognostic Index are prognostic indicators in patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.

Authors:  Akiko Miyagi Maeshima; Hirokazu Taniguchi; Suguru Fukuhara; Noriyuki Morikawa; Wataru Munakata; Dai Maruyama; Sung-Won Kim; Takashi Watanabe; Yukio Kobayashi; Kensei Tobinai; Hitoshi Tsuda
Journal:  Cancer Sci       Date:  2012-08-14       Impact factor: 6.716

7.  How I treat mantle cell lymphoma.

Authors:  David J Straus
Journal:  J Oncol Pract       Date:  2007-09       Impact factor: 3.840

Review 8.  Hemopoietic stem cell transplantation in T-cell malignancies: who, when, and how?

Authors:  Francesco d'Amore; Esa Jantunen; Thomas Relander
Journal:  Curr Hematol Malig Rep       Date:  2009-10       Impact factor: 3.952

Review 9.  Do recent reports of prolonged survival in patients with follicular lymphoma suggest that deferral of therapy is no longer justifiable?

Authors:  Brian K Link
Journal:  Curr Hematol Malig Rep       Date:  2007-10       Impact factor: 3.952

10.  Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.

Authors:  Efrat Dotan; Charu Aggarwal; Mitchell R Smith
Journal:  P T       Date:  2010-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.